SCHEMBL5727660

SCHEMBL5727660

CC(C)(Oc1cccc(OCCCl)c1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 12/20 0.57
▸ PPARD Q03181 5/20 0.57
▸ PPARG P37231 15/20 0.54
▸ MEN1 O00255 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ MAP4K4 O95819 1/20 0.48
▸ CYP4F2 P78329 1/20 0.46
▸ CYP4A11 Q02928 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5726752 0.94 PPARA (0.60) PPARAPPARDPPARGMEN1CYP1A2
SCHEMBL5726351 0.93 PPARA (0.58) PPARAPPARDPPARGMEN1CYP1A2
SCHEMBL5727212 0.86 PPARA (0.62) PPARAPPARDPPARGMEN1CYP1A2
SCHEMBL14060871 0.83 LMNA (0.64) PPARAPPARDPPARGMEN1CYP1A2
SCHEMBL5892213 0.83 PPARA (0.57) PPARAPPARDPPARGCYP1A2CYP3A4
SCHEMBL5660178 0.81 PPARA (0.53) PPARAPPARDPPARGCYP4F2CYP4A11
SCHEMBL5727498 0.80 PPARG (0.62) PPARAPPARDPPARGMEN1CYP1A2
SCHEMBL5892268 0.79 PPARA (0.47) PPARAPPARDPPARGCYP1A2CYP2D6
SCHEMBL7988206 0.79 PPARA (0.55) PPARAPPARDPPARGMEN1CYP1A2
SCHEMBL5659323 0.79 PPARA (0.54) PPARAPPARDPPARGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1502590-B1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes SERVIER LAB (FR) 2006-12-20 — — EP disclosed
EP-1502590-A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes Les Laboratoires Servier (FR) 2005-02-02 — — EP disclosed
Send feedback